Welcome to our dedicated page for Surrozen SEC filings (Ticker: SRZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Surrozen filings document a biotechnology issuer focused on Wnt signaling and antibody technologies for ophthalmic disease. Recent Form 8-K reports disclose operating results, financial condition, pipeline business updates for SZN-8141 and related retinal disease programs, and collaboration and license revenue tied to research milestones.
The company's regulatory reports also record governance and compensation matters, including board and executive changes and inducement equity arrangements, along with material-agreement disclosures such as the termination of the TCGFB collaboration for antibody discovery services. Cover-page data and exhibits identify Surrozen common stock and redeemable warrants as part of the public-company capital structure.
Surrozen reported first quarter 2026 results that pair advancing eye-disease programs with heavy non-cash losses tied to financing structures. The company is progressing lead retinal candidates SZN-8141 and SZN-8143 and remains on track to submit an Investigational New Drug application for SZN-8141 in the second half of 2026.
Collaboration and license revenue was $5.0 million, driven by a Boehringer Ingelheim milestone for SZN-413, while cash and cash equivalents rose to $106.9 million as of March 31, 2026 from $89.2 million at year-end. Research and development expenses increased to $9.3 million and general and administrative expenses to $6.1 million as the ophthalmology portfolio scales up.
Net loss widened sharply to $127.5 million, or ($11.65) per share, compared with $27.0 million, or ($7.43) per share, a year earlier. The larger loss primarily reflects a $76.9 million non-cash loss on change in fair value of tranche liability related to the 2025 PIPE and a $41.1 million other expense, mainly from an $81.7 million non-cash increase in warrant liabilities. As of March 31, 2026, tranche liability was $235.5 million and warrant liabilities were $148.9 million, contributing to a stockholders’ deficit of $278.1 million.
Surrozen executive Li Yang reported routine equity transactions tied to restricted stock units (RSUs). On May 1, 2026, Yang exercised 4,375 RSUs, receiving an equal number of Surrozen common shares at a conversion price of $0.00 per share. Each RSU represents a contingent right to one share of common stock.
On May 4, 2026, 1,584 common shares were sold at a weighted average price of $33.33 per share to cover withholding taxes upon RSU vesting, in transactions initiated by Surrozen. These sales occurred in multiple trades between $33.04 and $33.63 per share. After the sale, Yang directly held 17,216 common shares and also reported indirect holdings of 351 shares for a son and 351 shares for a daughter. The reported RSUs vest in two equal installments on May 1, 2026 and May 1, 2027.
Surrozen (SRZN) Chief Operating Officer Charles O. Williams reported routine equity compensation activity and related tax sales. On May 1, 2026, he exercised 5,625 Restricted Stock Units (RSUs) at $0.00 per share, receiving the same number of common shares. On May 4, 2026, 2,036 common shares were sold at a weighted average price of about $33.33 per share to cover withholding taxes, in transactions initiated by the company on his behalf. After these transactions, he directly holds 16,571 common shares. The filing also notes RSUs scheduled to vest in two equal installments on May 1, 2026 and May 1, 2027.
Surrozen, Inc. Chief Executive Officer Craig C. Parker reported routine equity compensation activity and related tax sales. On May 1, 2026, he exercised 12,500 Restricted Stock Units, each converting into one share of common stock at $0.00, increasing his direct holdings to 21,077 shares.
On May 4, 2026, 4,524 common shares were sold at a weighted average price of $33.3328 per share to cover withholding taxes upon RSU vesting in transactions initiated by the company on his behalf. After these transactions, Parker directly held 16,553 common shares. A remaining RSU award of 12,500 units is scheduled to vest in two equal installments on May 1, 2026 and May 1, 2027.
Surrozen, Inc. reports a Schedule 13G showing Point72-affiliated entities beneficially own 615,957 shares of Common Stock, representing 5.4% of the class as of April 22, 2026.
The filing states Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen share voting and dispositive power over these shares through Point72 Associates; Point72 Associates holds the economic interest.
Surrozen, Inc. executive Li Yang reported a charitable stock gift. As Executive Vice President of Research, Yang made a bona fide gift of 1,666 shares of Surrozen common stock on March 31, 2026, with no sale proceeds because gifts are transferred without payment.
After this donation, Yang directly holds 14,425 shares of common stock. The filing also shows indirect ownership of 351 shares held by a daughter and 351 shares held by a son, which are reported as indirect family holdings rather than direct trades in the market.
Surrozen, Inc. filed a prospectus to offer up to $50,000,000 of common stock through an at‑the‑market sales agreement with TD Securities (USA) LLC (TD Cowen). The company may sell shares from time to time on Nasdaq or other trading markets under the Sales Agreement dated March 23, 2026.
The prospectus states an assumed reference price of $25.15 per share (last reported sale price on March 20, 2026) and illustrates that up to 11,762,608 shares could be issued if the full $50,000,000 aggregate amount is sold at that price. Proceeds are intended for working capital and general corporate purposes, and TD Cowen may receive up to 3.0% of gross proceeds as compensation.
Surrozen, Inc. reported open-market share purchases by affiliated TCG Crossover funds. On March 23–24, entities associated with TCG Crossover Fund II and Fund III bought a combined 121,881 shares of Surrozen common stock in multiple open-market transactions at prices around $24.90 and $24.69 per share.
The Form 4 shows these positions as indirect holdings, with the shares held of record by TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P. After these buys, the reporting entities disclose indirect ownership levels between 683,218 and 736,554 shares across the noted positions, reinforcing their status as significant, greater-than-10% shareholders.